Why the study?
In systemic light-chain amyloidosis, cardiac involvement portends poor prognosis, and using MRI myocardial characteristics to detect early alterations, monitor treatment response, and predict MACE risk required evaluation.
Does left ventricular extracellular volume (ECV) on MRI predict major adverse cardiac events and detect early myocardial alterations in patients with systemic AL amyloidosis?
Cohort (n=80)
Yes
Does left ventricular extracellular volume (ECV) on MRI predict major adverse cardiac events and detect early myocardial alterations in patients with systemic AL amyloidosis?
In systemic AL amyloidosis, LV ECV on MRI detects subclinical cardiomyopathy, tracks treatment response, and provides excellent risk stratification for MACE beyond the standard Mayo AL stage.
Answers are grounded in this paper and cite their sources.
May support early MRI monitoring in AL amyloidosis; hypothesis-generating for MACE prediction and therapy response.
Aims: In systemic light-chain (AL) amyloidosis, cardiac involvement portends poor prognosis. Using myocardial characteristics on magnetic resonance imaging (MRI), this study aimed to detect early myocardial alterations, to analyze temporal changes with plasma cell therapy, and to predict risk of major adverse cardiac events (MACE) in AL amyloidosis. Methods and Results: Participants with recently diagnosed AL amyloidosis were prospectively enrolled. Presence of AL cardiomyopathy (AL-CMP vs. AL-non-CMP) was determined by abnormal cardiac biomarkers. MRI was performed at baseline and 6 months, with 12-month imaging in AL-CMP cohort. MACE was defined as all-cause death, heart failure hospitalization, or cardiac transplantation. Mayo AL stage was based on troponin T, NT-proBNP, and difference in free light chains. The study cohort included 80 participants (median age 62 years, 58% males). Median left ventricular extracellular volume (ECV) was significantly higher in AL-CMP (53% vs. 30%, p<0.001). ECV was abnormal (>32%) in all AL-CMP and in 47% of AL-non-CMP. ECV tended to increase at 6 months and decreased significantly from 6 to 12 months in AL-CMP (median -3%, p=0.011). ECV was strongly associated with MACE (p<0.001), and improved MACE prediction when added to Mayo AL stage (p=0.002). ECV≤32% identified a cohort without MACE, while ECV>48% identified a cohort with 74% MACE. Conclusions: In AL amyloidosis, ECV detects subclinical cardiomyopathy. ECV tends to increase from baseline to 6 months and decreases significantly from 6 and 12 months of plasma cell therapy in AL-CMP. ECV provides excellent risk stratification and offers additional prognostic performance over Mayo AL stage.
No takes yet. Share an insight, caveat, or question.
Clerc et al. (2023) conducted a cohort in Systemic light-chain (AL) amyloidosis (n=80). Left ventricular extracellular volume (LV ECV) >48% vs. LV ECV ≤32% was evaluated on Major adverse cardiac events (MACE) (p=<0.001).
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: